 | Up a level |
Hermann, Laura; Schöning, Verena; Dräger, Sarah; Rentsch, Katharina; Moser, Stephan; Gürtler, Nicolas; Sendi, Parham; Osthoff, Michael; Hammann, Felix (2024). Population pharmacokinetics of flucloxacillin as intermittent bolus infusion in patients with Staphylococcus aureus bloodstream infection. The journal of antimicrobial chemotherapy, 79(8), pp. 2031-2039. Oxford University Press 10.1093/jac/dkae207
Urwyler, Pascal; Leimbacher, Marina; Charitos, Panteleimon; Moser, Stephan; Heijnen, Ingmar A F M; Trendelenburg, Marten; Thoma, Reto; Sumer, Johannes; Camacho-Ortiz, Adrián; Bacci, Marcelo R; Huber, Lars C; Stüssi-Helbling, Melina; Albrich, Werner C; Sendi, Parham; Osthoff, Michael (2023). Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial. Frontiers in immunology, 14(1255292), p. 1255292. Frontiers Research Foundation 10.3389/fimmu.2023.1255292
Urwyler, Pascal; Moser, Stephan; Trendelenburg, Marten; Sendi, Parham; Osthoff, Michael (2022). Targeting thromboinflammation in COVID-19 - A narrative review of the potential of C1 inhibitor to prevent disease progression. Molecular immunology, 150, pp. 99-113. Elsevier 10.1016/j.molimm.2022.08.008
Moser, Stephan; Rehm, Sophia; Guertler, Nicolas; Hinic, Vladimira; Dräger, Sarah; Bassetti, Stefano; Rentsch, Katharina M; Sendi, Parham; Osthoff, Michael (2021). Probability of pharmacological target attainment with flucloxacillin in Staphylococcus aureus bloodstream infection: a prospective cohort study of unbound plasma and individual MICs. The journal of antimicrobial chemotherapy, 76(7), pp. 1845-1854. Oxford University Press 10.1093/jac/dkab089
Urwyler, Pascal; Charitos, Panteleimon; Moser, Stephan; Heijnen, Ingmar A F M; Trendelenburg, Marten; Thoma, Reto; Sumer, Johannes; Camacho-Ortiz, Adrián; Bacci, Marcelo R; Huber, Lars C; Stüssi-Helbling, Melina; Albrich, Werner C; Sendi, Parham; Osthoff, Michael (2021). Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19). Trials, 22(1), p. 1. BioMed Central 10.1186/s13063-020-04976-x
